A Vancomycin, monohydrochloride CEP of the European Pharmacopoeia monograph is often referred to as a Vancomycin, monohydrochloride Certificate of Suitability (COS). The purpose of a Vancomycin, monohydrochloride CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Vancomycin, monohydrochloride EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Vancomycin, monohydrochloride to their clients by showing that a Vancomycin, monohydrochloride CEP has been issued for it. The manufacturer submits a Vancomycin, monohydrochloride CEP (COS) as part of the market authorization procedure, and it takes on the role of a Vancomycin, monohydrochloride CEP holder for the record. Additionally, the data presented in the Vancomycin, monohydrochloride CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Vancomycin, monohydrochloride DMF.
A Vancomycin, monohydrochloride CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Vancomycin, monohydrochloride CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Vancomycin, monohydrochloride suppliers with CEP (COS) on PharmaCompass.